Ravil R. Petrov

TL;DR: A novel class of compounds whose physiological and therapeutic actions are mediated through block of Cav3.2 calcium channels is revealed, which was efficacious in mediating analgesia in mouse models of acute inflammatory pain and in reducing tactile allodynia in the partial nerve ligation model.

TL;DR: This work shows that both T-type channels as well as CB2 receptors play a role in the antinociceptive action of NMP-181, and also provides a novel avenue for suppressing chronic pain through novel mixed T- type/cannabinoid receptor ligands.

TL;DR: The present study provides novel tricyclic series as a starting point for further investigations of CB2 pharmacology and pain treatment and identified the CB2 ligand 35 which failed to promote CB2 receptor internalization and inhibited compound CP55,940-induced CB2 internalization.

TL;DR: The results reveal that a set of novel cannabinioid receptor ligands potently inhibit T- type calcium channels and show analgesic effects in vivo, and suggest possible novel means of mediating pain relief through mixed T-type/cannabinoid receptor ligANDs.

TL;DR: This work shows that NMP-7 mediates a significant analgesic effect in a model of persistent inflammatory and chronic neuropathic pain by way of T-type channel modulation and CB2 receptor activation, and provides a novel therapeutic avenue for managing chronic pain conditions via mixed CB ligands/T-type channels.